Northern Trust Corp Increases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Northern Trust Corp increased its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 16.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 659,788 shares of the company's stock after purchasing an additional 92,933 shares during the period. Northern Trust Corp owned approximately 0.87% of Nurix Therapeutics worth $12,430,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in NRIX. FMR LLC boosted its position in shares of Nurix Therapeutics by 1,711.9% during the 4th quarter. FMR LLC now owns 10,634,231 shares of the company's stock worth $200,349,000 after purchasing an additional 10,047,329 shares during the period. Vanguard Group Inc. boosted its position in shares of Nurix Therapeutics by 8.3% during the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock worth $81,865,000 after purchasing an additional 333,452 shares during the period. Norges Bank purchased a new position in shares of Nurix Therapeutics during the 4th quarter worth approximately $6,006,000. Nikko Asset Management Americas Inc. boosted its position in shares of Nurix Therapeutics by 42.8% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after purchasing an additional 236,620 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Nurix Therapeutics by 42.7% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after purchasing an additional 235,971 shares during the period.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,438 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $28,037.00. Following the transaction, the chief financial officer now owns 39,922 shares in the company, valued at $459,103. This trade represents a 5.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $38,835.50. Following the transaction, the insider now owns 61,516 shares in the company, valued at $707,434. This represents a 5.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,838 shares of company stock valued at $221,500 over the last ninety days. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock traded up $0.21 during trading on Thursday, hitting $9.99. 599,909 shares of the stock were exchanged, compared to its average volume of 873,601. The stock has a market cap of $761.60 million, a price-to-earnings ratio of -3.46 and a beta of 2.23. The firm's 50-day moving average price is $10.75 and its 200 day moving average price is $16.50. Nurix Therapeutics, Inc. has a 12-month low of $8.18 and a 12-month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.05. The business had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. During the same period in the previous year, the company earned ($0.76) EPS. As a group, research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Royal Bank of Canada increased their price objective on shares of Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 29th. Wells Fargo & Company decreased their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Needham & Company LLC reissued a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Wall Street Zen cut shares of Nurix Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday. Finally, HC Wainwright reissued a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.